Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Molecular testing in malignant melanoma.

Grossmann AH, Grossmann KF, Wallander ML.

Diagn Cytopathol. 2012 Jun;40(6):503-10. doi: 10.1002/dc.22810. Review.

PMID:
22619125
2.

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.

Hum Pathol. 2005 May;36(5):486-93.

PMID:
15948115
3.

Oncogenetics of melanoma: basis for molecular diagnostics and therapy.

Held L, Eigentler TK, Meier F, Held M, Röcken M, Garbe C, Bauer J.

J Dtsch Dermatol Ges. 2011 Jul;9(7):510-6. doi: 10.1111/j.1610-0387.2011.07603.x. Epub 2011 Jan 19. Review. English, German.

PMID:
21244632
4.

Molecular biology of melanoma.

Swick JM, Maize JC Sr.

J Am Acad Dermatol. 2012 Nov;67(5):1049-54. doi: 10.1016/j.jaad.2011.06.047. Epub 2012 Mar 28. Review.

PMID:
22459362
5.

Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology.

Holden JA, Willmore-Payne C, Layfield LJ.

Exp Mol Pathol. 2008 Aug;85(1):68-75. doi: 10.1016/j.yexmp.2008.03.010. Epub 2008 Apr 10.

PMID:
18486128
6.

Preappointment testing for BRAF/KIT mutation in advanced melanoma: a model in molecular data delivery for individualized medicine.

Mounajjed T, Brown CL, Stern TK, Bjorheim AM, Bridgeman AJ, Rumilla KM, McWilliams RR, Flotte TJ.

Hum Pathol. 2014 Nov;45(11):2240-6. doi: 10.1016/j.humpath.2014.07.009. Epub 2014 Jul 30.

7.

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.

Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W.

PLoS One. 2012;7(4):e35309. doi: 10.1371/journal.pone.0035309. Epub 2012 Apr 20.

8.

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.

Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H, Okuyama R.

Br J Cancer. 2012 Feb 28;106(5):939-46. doi: 10.1038/bjc.2012.12. Epub 2012 Jan 26.

9.

BRAF and c-kit gene copy number in mutation-positive malignant melanoma.

Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ.

Hum Pathol. 2006 May;37(5):520-7.

PMID:
16647948
10.

Detection of BRAF gene mutation in primary choroidal melanoma tissue.

Malaponte G, Libra M, Gangemi P, Bevelacqua V, Mangano K, D'Amico F, Mazzarino MC, Stivala F, McCubrey JA, Travali S.

Cancer Biol Ther. 2006 Feb;5(2):225-7. Epub 2006 Feb 20.

PMID:
16410717
11.

Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases.

Langer R, Becker K, Feith M, Friess H, Höfler H, Keller G.

Mod Pathol. 2011 Apr;24(4):495-501. doi: 10.1038/modpathol.2010.220. Epub 2010 Dec 3.

12.

[Translational research and diagnostics of melanoma].

Rüschoff J, Kleinschmidt M, Middel P.

Pathologe. 2012 Nov;33 Suppl 2:291-5. doi: 10.1007/s00292-012-1661-1. Review. German.

PMID:
22968732
13.

Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.

Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, Molven A.

Melanoma Res. 2008 Feb;18(1):29-35. doi: 10.1097/CMR.0b013e3282f32517.

PMID:
18227705
14.

New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances.

Flaherty KT, Fisher DE.

Clin Cancer Res. 2011 Aug 1;17(15):4922-8. doi: 10.1158/1078-0432.CCR-10-2612. Epub 2011 Jun 13. Review.

15.

RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.

Dadzie OE, Yang S, Emley A, Keady M, Bhawan J, Mahalingam M.

Br J Dermatol. 2009 Feb;160(2):368-75. doi: 10.1111/j.1365-2133.2008.08887.x. Epub 2008 Oct 20.

PMID:
18945298
16.

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Platz A, Egyhazi S, Ringborg U, Hansson J.

Mol Oncol. 2008 Apr;1(4):395-405. doi: 10.1016/j.molonc.2007.12.003. Epub 2007 Dec 28.

17.

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

Nissan MH, Solit DB.

Curr Oncol Rep. 2011 Dec;13(6):479-87. doi: 10.1007/s11912-011-0198-4. Review.

PMID:
21997758
18.

Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.

Lázár V, Ecsedi S, Vízkeleti L, Rákosy Z, Boross G, Szappanos B, Bégány A, Emri G, Adány R, Balázs M.

Melanoma Res. 2012 Jun;22(3):202-14. doi: 10.1097/CMR.0b013e328352dbc8.

PMID:
22456166
19.

KIT gene mutations and copy number in melanoma subtypes.

Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL.

Clin Cancer Res. 2008 Nov 1;14(21):6821-8. doi: 10.1158/1078-0432.CCR-08-0575.

20.

Assessment of BRAF and KIT mutations in Japanese melanoma patients.

Ashida A, Uhara H, Kiniwa Y, Oguchi M, Murata H, Goto Y, Uchiyama A, Ogawa E, Hayashi K, Koga H, Okuyama R.

J Dermatol Sci. 2012 Jun;66(3):240-2. doi: 10.1016/j.jdermsci.2012.03.005. Epub 2012 Apr 5. No abstract available.

PMID:
22534474
Items per page

Supplemental Content

Write to the Help Desk